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ABSTRACT
This study was designed to test the hypothesis that decellularized pancreatic matrices seeded with adult-derived 
endogenous stem cells and donor islets provide an optimal environment for islets to secrete insulin in response to a 
glucose challenge. Adult animals were euthanized following the guidelines of Fort Valley State University-IACUC 
and Mercer University-IACUC. Adult porcine pancreases were decellularized using a mixture of detergents. 
Adult rat pancreatic islets were obtained by lipase digestion followed by Ficoll gradient sedimentation. Control 
cultures consisted of decellularized matrices, clonal populations of naïve adult totipotent and pluripotent stem 
cell populations, and rat islets, all cultured individually. Experimental groups consisted of islets co-cultured with 
clonal populations of pluripotent stem cells and totipotent stem cells seeded on decellularized matrices. Control 
and experimental cultures were challenged with the insulin secretagogue glucose. The control and culture media 
were removed and stored at -20oC until assayed using a RIA specific for rat insulin. The culture media, containing 
bovine insulin, were assayed using a RIA specific for rat insulin. No detectable levels of insulin (bovine, rat, human, 
or porcine) were noted in media only, the stem cell populations or the decellularized matrices, respectively. Native 
pancreatic islets secreted nanogram quantities of insulin per nanogram of DNA. Pancreatic islets co-cultured 
with naïve stem cells and matrices demonstrated increased insulin secretion in the range of milligram quantities 
of insulin per nanogram of DNA, i.e., a 250-fold increase in insulin secretion in response compared to pancreatic 
islets alone. These studies suggest that native islets in combination with decellularized matrices and adult-derived 
pluripotent and totipotent stem cells could provide more tissue for pancreatic islet transplants than donor islets 
alone.
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Introduction
Diabetes mellitus is a metabolic syndrome with a diversity of 
etiologies, clinical presentations, and outcomes. It is characterized 
by insulinopenia, fasting or postprandial hyperglycemia, and 
insulin resistance. Type 1 diabetes mellitus, referred to as juvenile 
or insulin-dependent diabetes mellitus (IDDM), is typically 
characterized by insulinopenia, hyperglycemia, and secondary 
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insulin resistance [1]. It is an autoimmune disease whereby 
CD8+ T-cells destroy the insulin-producing pancreatic β-cells 
[2]. Type 2 diabetes mellitus, referred to as adult onset or non-
insulin-dependent diabetes mellitus (NIDDM), is characterized by 
hyperglycemia and varying degrees of primary insulin resistance 
with elevated plasma insulin concentrations, but a decreased 
insulin response to challenge by a secretagogue [3,4]. Diabetes 
mellitus need not be overt and grossly hyperglycemic to induce 
detrimental metabolic changes. A growing body of evidence 
suggests that there are detrimental consequences to normal 
physical challenges such as aging, which may be inherently linked 
to alterations in body composition. Such challenges may result 
in subclinical diabetogenic changes. It is becoming increasingly 
clear that loss of physical strength, functional status, and immune 
competence are related to decreases in lean body mass observed in 
diabetogenic states [5-7]. 
Walsh and colleagues in 1933 showed that the protein wasting 
that was present in type-I diabetes mellitus could be eliminated 
by administration of insulin [8]. Later studies suggested that the 
degree of protein wasting may be related to insulin availability 
and the degree of pancreatic function [9]. A single mechanism 
of action, which describes the effect of insulin on proteolysis or 
proteogenesis, remains to be clearly elucidated. Decreased lean 
body mass in diabetes mellitus may be due to decreased number 
and translational efficiency of ribosomes [10,11] and to alterations 
in peptide chain elongation and termination [12]. Several studies 
additionally suggest that these effects may be modulated in 
part by modifications in insulin-like growth factor I (IGF-I). 
Streptozotocin diabetic rats that are insulin-deficient lack IGF-I 
[13]. Growth retardation in diabetic infants has been ascribed to 
a lack of proper insulinization [14]. More recent studies suggest 
that protein nutrition, insulin, and growth may be modulated via 
IGF-I [15,16]. 
While temporary control of hypoglycemia, euglycemia and 
hyperglycemia can occur in diabetic mellitus patients with the 
injection of insulin, exogenous insulin administration is not 
equivalent to the sensitive monitoring of glucose and release of 
insulin or glucagon by endogenous pancreatic islets to facilitate 
euglycemia [17]. Unless constant glucose monitoring occurs, 
even tightly controlled patients are at risk for potentially fatal 
hypoglycemic episodes due to the inability of pancreatic islets to 
correct for a decrease in insulin release and an increase in glucagon 
release due to a decrease in circulating glucose [18]. Unregulated 
hypoglycemia and/or hyperglycemia can lead to long term 
complications including cardiovascular disease, neuropathies, 
nephropathies, and retinopathies [19]. 
Tobin et al. [20,21] demonstrated that transplantation with normal 
pancreatic islets of Langerhans completely restores normal body 
protein levels in rats. The transplantation of pancreatic islets 
rather than the entire pancreas has been investigated as a possible 
treatment for type-1 diabetes mellitus in selected patients that were 
unresponsive to exogenous insulin therapy [22]. The Edmonton 
group [23-26] reported that sufficient islet mass from as few 
as two pancreases, in combination with a regimen involving a 
glucocorticoid-free immunosuppressive protocol, engendered 
sustained freedom (>1 year) of insulin independence in eight 
of eight [24] and 12 of 12 [25,26] patients with type-1 diabetes 
mellitus. Their findings indicated that islet transplantation alone 
was associated with minimal risk and resulted in good metabolic 
control [24,27]. However, due to the shortage of cadaver organ 
donors, less than 0.5% of patients with type-1 diabetes mellitus 
are able to receive an islet transplant at the present time. Thus, 
alternative sources of insulin-secreting tissue were urgently needed 
[23]. Reports by Cornelius et al. [28], Ramiya et al. [26], and 
Bonner-Weir et al. [30] suggest that reversal of insulin-dependent 
diabetes mellitus can be accomplished using chemically induced 
islets generated in vitro from pancreatic ductal endodermal stem 
cells. In addition, Lumelsky et al. [31] and Rajagopal et al. [32] 
reported the formation of pancreatic beta cells that spontaneously 
differentiated from embryonic stem cells. 
Young and colleagues [33,34] discovered primitive stem cell 
populations that were located within the connective tissue 
compartments of adult mammals, including humans. Six 
populations of primitive stem cells discovered thus far were 
termed totipotent stem cells (TSCs) [35], transitional-totipotent/
pluripotent stem cells (Tr-T/PSCs) [34], pluripotent stem cells 
(PSCs) [36,37], mesodermal stem cells [38], ectodermal stem 
cells, and endodermal stem cells [36,37]. A pluripotent stem 
cell clone was derived from male outbred Sprague-Dawley rats 
by single cell by repetitive limiting serial dilution clonogenic 
analysis. Scl-4β could be induced to form 63 objectively verifiable 
cell types across all three germ layer lineages after incubation in 
a general induction medium [33,36,37]. A transitional-totipotent/
pluripotent stem cell clone, Scl-40β, derived from a single cell 
by repetitive limiting serial dilution clonogenic analysis could be 
induced to form a minimum of 64 objectively verifiable cell types 
across all three germ layer lineages after incubation in a general 
induction medium [33,34]. Totipotent stem cell clones, Scl-9β 
and Scl-44β, were derived from male outbred Sprague-Dawley 
rats by single cell by repetitive limiting serial dilution clonogenic 
analysis. The totipotent stem cell clones could be induced to form 
66 objectively verifiable cell types after incubation in a general 
induction medium [33,39]. Pluripotent stem cells were noted to be 
6-8 microns in size [36,37], totipotent stem cells were noted to be 
less than two microns in size [35]; and the transitional-totipotent/
pluripotent stem cells were noted to be 3-5 microns in size [34,35]. 
These primitive adult-derived stem cells demonstrated other 
unique qualities that set them aside from other more differentiated 
adult stem cell populations (Table 1) [33-37].
Based on the studies of Lumelsky et al. [31] and Rajagopal et al. 
[32] in which embryonic stem cells were allowed to spontaneously 
differentiate in vitro into insulin secreting pancreatic β-cells, Young 
and Black [40] began a series of preliminary studies to ascertain 
the ability of adult-derived pluripotent stem cells to be induced 
de novo into pancreatic-like structures as a method to supplement 
existing pancreatic islet tissue for transplant. Beginning with a 
clonal population of adult-derived pluripotent stem cells these 
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Table 1: Characteristics of Differentiated Cells, Progenitor Cells and Stem Cells.
1. DC, differentiated cells, 2. PC, progenitor cells, 3. GLSC, germ layer lineage stem cell, 4. PSC, pluripotent stem cell, 5. Tr-T/PSC, transitional-totipotent/pluripotent 
stem cell, 6. TSC, totipotent stem cell, 7. Var, variable, 8. Viabil P. Mortem, viability of tissue post mortem (after removal from the body) stored at 4oC, 9. STs, solid 
tissues, 10. CTs, connective tissues, 11. BM, bone marrow, 12. Bld, blood, 13. Qui, quiescence, 14. NA, not applicable, 15. Tel’ase, telomerase, 16. PD, population 
doublings, 17. PR, proliferation rate, 18. D-W, days to weeks, 19. CD, cell doublings, 20. NYD, not yet determined, 21. CI-C, cell inhibition at confluence, 22. GT-1C, 
growth on type-1 collagen substrate, 23. G-S, growth in cell suspension cultures, 24. R-Prolif, response to proliferation factors, 25. R-Prog, response to progression agents, 
26. R-Induc, response to induction factors, 27. R-Inhib, response to inhibitory factors, 28. #Cs-Fr, number of cells frozen, 29. Freeze Agent, cryopreservation agent, 30. 
DMSO, dimethylsulfoxide, 99.99% pure, 31. Temp, optimum freezing temperature in centigrade, 32. FrProc, freezing process, 33. ThwProc, thawing process, 34. Recov, 
% recovery from freezing process, 35. RC-1C, rat clones derived from one cell, 36. CsFmd, cells formed, 37. CD-Ms, cluster of differentiation (CD) markers.
investigators utilized three separate and selective inductive 
cocktails to systematically induce the pluripotent stem cells to 
form endodermal stem cells then to form pancreatic progenitor 
cells and finally to form three-dimensional pancreatic islet-like 
structures that stained for insulin, glucagon, and somatostatin. 
Following the protocol of Lumelsky et al. [31] for a sequential 
glucose challenge, except using a Rat-specific insulin 
radioimmunoassay (RIA) instead of the non-specific insulin-RIA 
as used by Lumelsky [31], Young and Black [40] demonstrated 
that the three-dimensional structures, generated de novo from 
adult-pluripotent stem cells, secreted one-quarter to one-half the 
amount of insulin secreted by native islets. This was in contrast to 
de novo-generated pancreatic progenitor cells that secreted one-
half to 100% of the insulin secreted by native islets. 
These results contrasted with those of Lumelsky et al. [31] and 
Rajagopal et al. [32] in which they demonstrated that pancreatic 
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beta cells derived from embryonic stem cells would produce 1/20th 
(5%) of the amount of insulin as compared to native islets. Their 
suggestion was to implant more embryonic stem cell-derived beta-
cells to increase the amount of insulin output from the transplant. 
The procedure developed by Young and Black [40] to generate 
pancreatic islet-like structures de novo utilized three induction 
cocktails, i.e., conditioned media from endodermal stem cells 
to convert pluripotent stem cells to endodermal stem cells; 
conditioned medium from pancreatic progenitor cells to convert 
endodermal stem cells to pancreatic progenitor cells; and a defined 
cocktail of known pancreatic islet inductive agents [30] to convert 
pancreatic progenitor cells into pancreatic islet-like structures 
consisting of glucagon secreting alpha-cells, insulin secreting 
beta-cells, and somatostatin secreting delta-cells. Unfortunately, 
due to the conditioned media containing quantities of unknown 
animal proteins, the procedure was deemed problematic as a basis 
for therapy in humans. To avoid the use of conditioned media, the 
current study utilized the co-culture of (recipient, autologous) adult 
pluripotent stem cells and adult totipotent stem cells with (donor, 
allogeneic) adult native islets on a decellularized porcine pancreatic 
matrix. The resultant cultures were challenged sequentially with 
glucose to determine their respective insulin response.
Materials and Methods
Animal Use
The porcine experiments followed the guidelines of Fort Valley 
State University’s IACUC. The rodent experiments followed 
the guidelines of Mercer University’s IACUC. Their respective 
IACUC guidelines reflect the criteria for humane animal care 
of the National Research Council as outlined in “Guide for the 
Care and Use of Laboratory Animals” prepared by the Institute 
of Laboratory Animal Resources and published by the National 
Institutes of Health (National Academy Press, 1996).
Pancreatic Tissue Harvest
Porcine
Two porcine experiments were conducted simultaneously. One 
experiment [42] examined the effect of trauma on the appearance 
of pluripotent and totipotent stem cells within the peripheral 
vasculature. The second experiment, reported herein, describes 
the use of xenogeneic decellularized native porcine pancreatic 
extracellular matrix (ECM) as a scaffold for endogenous 
pluripotent and totipotent stem cells co-cultured with donor 
islets creating composite pancreatic islet organoids as a potential 
treatment modality for insulin-dependent diabetes. The combined 
procedure is as follows.
Twenty adult 120 lb. female Yorkshire pigs (n=20) were 
anesthetized with tiletamine and zolazepam, then prepared for 
surgery with a Betadine wash and draped in a sterile fashion. A 
10-mL pre-trauma blood sample was obtained from the jugular 
vein. The blood was collected in a 10-ml EDTA hemovac tube 
(Becton-Dickinson), inverted several times to mix and placed 
on ice until further processing to isolate endogenous stem cells 
within the peripheral blood [41]. A midline laparotomy incision 
was performed. A piece of the right rectus abdominis muscle was 
obtained (pre-trauma) and placed into ice-cold transport solution 
(Moraga Biotechnology Corp., Los Angeles. CA). The spleen 
was isolated and resected. The abdominal aorta was isolated 
above the celiac trunk and below the renal arteries for insertion 
of a vascular cannula for infusion of ice cold Hank's buffered salt 
solution (Grand Island Biological Company [GIBCO], Grand 
Island, NY), pH 7.4. The pancreas was then resected, placed into 
ice cold Hank’s buffered salt solution and placed on ice for further 
processing. Isolation and resection of both the spleen and pancreas 
represented the trauma model to ascertain whether massive trauma 
would initiate release of pluripotent stem cells and totipotent stem 
cells into the peripheral vasculature [41]. A piece of left rectus 
abdominis muscle was obtained (post-trauma) and placed into 
ice-cold transport solution. A 10-mL post-trauma blood sample 
was obtained from the jugular vein and processed similarly as the 
pre-trauma blood sample. The pigs were euthanized by anesthetic 
overdose. The time period from pre-trauma blood draw to post-
trauma blood draw approximated 90 minutes.
Rodent
For pancreatic islet tissue, 200 × 150 mm pancreatic islet equivalent 
units were isolated from pancreases taken from ~300g breeding 
age adult male Wistar Furth rats (n = 8) following the procedure 
described by Tobin and colleagues [13,20,21]. The rats were 
anesthetized with ketamine/Xylazine, then prepared for surgery 
with a Betadine wash and draped in a sterile fashion. A midline 
laparotomy incision was performed. A cannula was placed into 
the pancreatic duct and the pancreas infused with ice cold Hank’s 
Buffered Salts Solution (GIBCO), pH 7.4. The pancreases were 
then resected and the rats euthanized by anesthetic overdose [40].
Decellularization of Porcine Pancreas
The porcine pancreases were divided and placed into either 
sterile Decellularization Solution-A (Moraga Biotechnology 
Corporation, Inc., Los Angeles, CA) or sterile Decellularization 
Solution-B (Moraga) on a tissue rotator at 4oC for 3.5 months. 
Sterile solutions were changed every two weeks to assist in the 
decellularization process. The decellularized matrices were 
removed from the solutions and washed with medium to ensure that 
the decellularization solutions were removed from the matrices. 
Each wash solution was assessed with a cytotoxicity proliferation 
assay for primitive stem cell viability. It was noted that 11 wash 
solutions were necessary to rid the matrices of decellularization 
solutions for cell viability to equal the viability seen with pristine 
wash solution. After decellularization in solutions A and B, the 
matrices were completely denuded of cells and composed of both 
thick and thin filaments.
Isolation of Rat Pancreatic Islets
Adult rat pancreatic islets were isolated as previously described 
[13,20,21,40]. Adult rat pancreases were minced. The tissue 
was weighed and digested with the enzyme liberase. Islets were 
separated from the remaining pancreatic material by Ficoll gradient 
centrifugation utilizing a layered solution of 25%, 23%, 20%, and 
11%, Ficoll. Pancreatic islets used for human transplant studies 
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appear as a band of cells between the 20% and 23% gradients of 
Ficoll. Aliquots from the band between 11% and 20%, between 
20% and 23%, between 23% and 25%, and the cell pellet were 
stained with antibodies to pro-insulin, SSEA, and CEA-CAM-1 to 
confirm the identity of the isolated tissue, and we noted something 
peculiar. Pancreatic islets were located both in the band between 
20% and 23% Ficoll and in the cell pellet. In addition, besides 
the pancreatic islets in each of these two locations there were also 
SSEA+ pluripotent stem cells and CEA-CAM-1+ totipotent stem 
cells. The heaviest concentration of SSEA+ stem cells, CEA-
CAM-1+ stem cells and pancreatic islets was located in the cell 
pellet rather than in the band between 20% and 23% Ficoll. We 
therefore used the material from the cell pellet for the composite 
pancreatic organoids to maximize our chances for optimizing 
insulin release. 
Adult-Derived Pluripotent Stem Cells and Totipotent Stem 
Cells
Two adult outbred Sprague-Dawley rat-derived stem cell clones 
were utilized for this study, Scl-40β [36,37] and Scl-44β [35]. 
Based on the distinctive characteristics of each stem cell clone 
[33] (Table 1), including staining with antibodies selective for 
pluripotent stem cells (SSEA) and totipotent stem cells (CEA-
CAM-1), Scl-40β (CEA-CAM-1+ / SSEA+) was designated as 
an adult-derived transitional-totipotent/pluripotent stem cell clone 
and Scl-44β (CEA-CAM-1+ only) was designated as an adult-
derived totipotent stem cell clone. Both clones, Tr-T/PSC-Scl-40β 
and TSC-Scl-44β, were utilized in combination in an attempt to 
obtain the maximal beta-cell generation and thus insulin response 
possible.
Parameters for Glucose Challenge Study
Fifteen parameters were examined for the glucose challenge 
study: 1) Equine-derived type-I collagen matrix only (our 
standard substratum for the growth of endogenous stem cells); 2) 
decellularized porcine pancreatic matrix-A only; 3) decellularized 
porcine pancreatic matrix-B only; 4) equine-derived type-I 
collagen matrix + Tr-T/PSC-Scl-40β; 5) equine-derived type-I 
collagen matrix + TSC-Scl-44β; 6) equine-derived type-I collagen 
matrix + Tr-T/PSC-Scl-40β + TSC-Scl-44β; 7) equine-derived 
type-I collagen matrix + native rat pancreatic islets + native 
SSEA+/CEA-CAM-1+ cells; 8) porcine pancreatic matrix-A + 
Tr-T/PSC-Scl-40β; 9) porcine pancreatic matrix-A + TSC-Scl-
44β; 10) porcine pancreatic matrix-A + Tr-T/PSC-Scl-40β + 
TSC-Scl-44β; 11) porcine pancreatic matrix-B + Tr-T/PSC-Scl-
40β; 12) porcine pancreatic matrix-B + TSC-Scl-44β; 13) porcine 
pancreatic matrix-B + Tr-T/PSC-Scl-40β + TSC-Scl-44β; 14) 
porcine pancreatic matrix-A + Tr-T/PSC-Scl-40β + TSC-Scl-44β 
+ native rat pancreatic islets + native SSEA+/CEA-CAM-1+ cells; 
15) porcine pancreatic matrix-B + Tr-T/PSC-Scl-40β + TSC-Scl-
44β + native rat pancreatic islets + native SSEA+/CEA-CAM-1+ 
cells.
Equine-derived type-I collagen matrix and decellularized porcine 
extracellular matrices A & B were seeded with the TSC-Scl-44β 
and Tr-T/PSC-Scl-40β clones, both singly and in combination, 
and grown for seven days to allow integration of the clonal stem 
cells with the porcine matrices. All 15 parameters examined 
were incubated in 24-well plates in general culture medium for 
three days. The 15 parameters were challenged sequentially with 
glucose following the protocol developed by Lumelsky et al. 
[31] and practiced by Young and Black [40]. In brief, the general 
culture medium was removed. The 15 parameters examined were 
washed with Dulbecco’s Phosphate Buffered Saline (DPBS), and 
incubated with medium containing 5 mM glucose for 24 hours. 
After 24 hours, the first neutral medium was removed. The 15 
parameters were washed with DPBS, and then incubated with 
medium containing 5 mM glucose for one hour. After one hour, 
the second neutral medium was removed. The 15 parameters were 
washed with DPBS, and then incubated with medium containing 
25 mM glucose for one hour. After one hour the third medium, 
the challenge medium, was removed. Their respective neutral and 
challenge media were removed and assayed using a rat-specific 
insulin-radioimmunoassay (insulin-RIA) with positive and 
negative controls. The 15 parameters were washed with DPBS and 
returned to the normal culture medium. Normal culture medium 
was replaced every other day. The glucose challenge reported 
herein was performed 3 days after initial seeding with the rat 
pancreatic islets. However, only the combinatorial constructs (i.e., 
porcine ECM + TSC & Tr-T/PSC + pancreatic islets) survived 
past seven days in culture. The native rat islets on type-I collagen 
matrix began to disintegrate after the first glucose challenge and 
had completely disintegrated by 7 days in culture.
Insulin-RIAs
The amount of secreted insulin was determined by double antibody 
competitive binding radioimmunoassay using rat insulin standards 
and antibodies raised against rat-specific insulin (Linco, St. Louis) 
[40]. A series of positive and negative controls was performed 
to ensure that the RIA measured only rat insulin secreted into 
the medium and not bovine insulin taken up and subsequently 
released by the cells [32] or potentially porcine insulin from the 
decellularized porcine pancreatic matrices. The positive controls 
consisted of a concentration range of rat insulin standards included 
with the rat-specific RIA kit. The negative controls consisted of 
serum-free defined BLSC medium (Moraga Biotechnology 
Corporation, Los Angeles, CA) with and without the insulin 
secretagogues in a cell-free system. Because our glucose challenge 
media also contained a small amount of bovine insulin, its presence 
was monitored using the same concentration range (0.1 to 10 ng/
ml bovine insulin) as the rat insulin standards in the rat-specific 
RIA kit. Because our derived pancreatic organoids contained a 
porcine pancreatic matrix, the presence of porcine insulin was 
monitored using the same concentration range (0.1 to 10 ng/ml 
porcine insulin) as the rat insulin standards in the rat-specific 
RIA kit. No insulin was detected in any of the negative controls 
analyzed. DNA analysis was performed in each well of the tissue 
culture plate to standardize the amount of insulin released [40,42].
Cryosectioned Naive Pancreatic Islets
Breeding age outbred adult Sprague-Dawley rats were anesthetized 
with ketamine/xylazine, then prepared for surgery with a Betadine 
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wash and draped in a sterile fashion. A midline laparotomy incision 
was performed. A cannula was placed into the pancreatic duct and 
the pancreas infused with ice cold Hank’s Buffered Salts Solution 
(GIBCO), pH 7.4. The pancreas was then resected and the rats 
were euthanized [40]. The resected pancreases were then placed 
in ELICA fixative (Moraga Biotechnology Corporation, Los 
Angeles, CA). The tissue was fixed for 2 weeks and then rinsed 
with GIBCO’s Dulbecco’s Phosphate Buffered Saline (DPBS) 
(Invitrogen Corporation, Carlsbad, CA). 
The pancreases were embedded in Tissue Tek OCT Compound 
4583 (Miles Laboratory, Ames Division, Elkhart, IN) and then 
frozen at -20oC. The tissue was then sectioned on a Tissue Tek 
Cryostat II (GMI, Ramsey, MN) to a thickness of 7 microns. The 
sections were applied to positively charged slides (Mercedes 
Medical, Sarasota, FL) and stored at -20oC until stained.
The tissue sections were stained with the CEA-CAM-1 antibody 
for totipotent stem cells and the SSEA-4 antibody (Developmental 
Studies Hybridoma Bank, Iowa City, IA) for pluripotent stem 
cells. We used 1A4 (Sigma, St Louis, MO) as a positive procedural 
control to stain smooth muscle alpha-actin in the tunica media of 
the blood vessels within the pancreas. Negative procedural controls 
consisted of either PBS only, no primary antibody, no secondary 
antibody (Rat Adsorbed Biotinylated Anti-Mouse IgG, Vector 
Laboratories Inc., Burlingame, CA) or no tertiary probe (avidin 
HRP, Vector). The substrate used was AEC (Sigma). Five percent 
sodium azide (Sigma) and 30% hydrogen peroxide (Sigma) were 
used as blocking agents to inhibit endogenous peroxidases. The 
slides were removed from -20oC storage, allowed to come to 
ambient temperature and fixed with 95% Ethanol for 30 minutes and 
rinsed with PBS. The slides were then blocked in sodium azide and 
hydrogen peroxide for a total of 90 minutes and rinsed with PBS. 
The slides were next incubated with the primary antibodies for 60 
minutes and rinsed with PBS. The slides were then incubated with 
the secondary antibody for 60 minutes and rinsed with PBS. The 
slides were next incubated with the tertiary probe for 60 minutes 
and rinsed with PBS several times. The substrate was applied and 
allowed to incubate for 60 minutes. It was then rinsed off and the 
slide was coverslipped using VectaMount (Vector). 
The slides were photographed using a COOLPIX 995 digital 
camera and a Nikon Phase Contrast Fluorophot microscope. The 
digital photographs were cropped using Adobe Photoshop 7.0. 
Results
Porcine pancreases prior to decellularization consisted of cells and 
extracellular matrices (Figure 1). The decellularized matrices were 
removed from the detergent solutions and washed 11 times with 
medium to ensure that the cytotoxic decellularization solutions 
were removed from the matrices, as assessed by a cytotoxicity 
proliferation assay of primitive stem cells incubated in the wash 
solutions (Figure 2). After decellularization in solutions A and B, 
the matrices were completely denuded of cells and composed of 
both thick and thin filaments (Figure 3).
Figure 1: Scanning electron micrograph (SEM) of a cut section of native porcine 
pancreas before immersion into a decellularization solution.
Figure 2: Cytotoxicity cell proliferation assay. Cultures of BLSCs and ELSCs were 
plated, allowed to attach for 24 hours, washed with buffer, and then incubated with 
either naïve detergent (Dec), with culture medium incubated with decellularized 
pancreatic matrix and changed every 24 hours (W1-W11), or with naïve culture 
medium (Cont.). Solutions were replaced every other day. After 14 days, the cultures 
were assayed for total DNA content using standard fluorometric procedures (Young 
et al., 1992). Statistical analysis demonstrated that 8 to 11 media changes (asterisk) 
were necessary to remove the cytotoxic detergents from the decellularized matrices 
to allow cell viability.
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Figure 3: Decellularized pancreatic matrices. Scanning electron microscopy of 
pancreatic matrices after decellularization with detergent-A (3A) and detergent-B 
(3C). Note both thick (type-I collagen) and thin (glycoprotein) matrix filaments 
(mf). Bright field microscopy of pancreatic matrices after decellularization with 
detergent-A (3B) and detergent-B (3D). Note presence of blood vessels (bv) and 
both thick and thin matrix filaments (mf).
Ficoll gradient separation of pancreatic isolates noted islets 
present in the interface between 20% and 23% Ficoll. In contrast, 
the heaviest concentration of the primitive stem cells and the 
pancreatic islets were located in the cell pellet rather than in the 
band between 20% and 23% Ficoll. We therefore used the material 
from the cell pellet for this study to maximize our chances for 
optimizing insulin release (Figure 4).
Figure 4: Ficoll gradient separation of native pancreatic islets from adult sexually 
mature ~220g Wistar-Furth rats. After liberase digestion the wash material was 
loaded onto a Ficoll density gradient (11%, 20%, 23%, and 25%) and centrifuged. 
The fraction between 20% and 23% and the cell pellet below 25% Ficoll were 
stained with antibodies to pro-insulin to identify islets containing insulin secreting 
beta cells, carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) to 
identify totipotent stem cells (TSCs), and stage specific embryonic antigen (SSEA) 
to identify pluripotent stem cells (PSCs). Note that the “trashy” material (DAB 
substrate, black-stained material) within the cell pellet contains insulin secreting 
islets (column 1), totipotent stem cells (column 2), and pluripotent stem cells 
(column 3).
The glucose challenge reported herein was performed 3 days after 
the original plating. However, only the combinatorial constructs 
survived past seven days in culture (Figures 5 and 6) and actually 
increased in size with continued culture. The native rat islets on 
type-I collagen matrix began to disintegrate after the first glucose 
challenge (Figure 7) and had completely disintegrated by 7 days 
in culture.
Twelve of 15 parameters examined demonstrated absence of rat 
insulin after the glucose challenge. Only three parameters, i.e., 
7) equine-derived type-I collagen matrix + native rat pancreatic 
islets + native SSEA+/CEA-CAM-1+ cells, 14) porcine pancreatic 
matrix-A + PSC-Scl-40β + TSC-Scl-44β + native rat pancreatic 
islets, and 15) porcine pancreatic matrix-B + Tr-T/PSC-Scl-
40β + TSC-Scl-44β + native rat pancreatic islets, demonstrated 
measurable quantities of secreted rat insulin after the glucose 
challenge. Indeed, the combinatorial structures, i.e., decellularized 
porcine pancreatic matrices, Scl-40β clone of stem cells, Scl-44β 
clone of stem cells, and the pelleted material containing native 
islets and associated endogenous pluripotent and totipotent stem 
cells, demonstrated a statistically significant increase (denoted by 
the presence of asterisks) in insulin secretion normalized to DNA 
content after a glucose secretagogue challenge, compared to native 
islets with associated endogenous pluripotent and totipotent stem 
cells on type-I collagen matrix alone (Figure 8). 
Figure 5: Isolated rat pancreatic islets with endogenous TSC and PSC from cell 
pellet after Ficoll density gradient centrifugation. Cell pellets were grown on the 
TSC-PSC-pancreatic matrix-A constructs utilizing the standard TSC-based culture 
medium. A & B are rat islets 48 hours after plating. C & D are rat islets 72 – 96 
hours after plating. Note that islets in C & D are increasing their three-dimensional 
integrity. These composites consisting of decellularized pancreatic matrix-A, Scl-
44β TSCs, Scl-40β PSCs, and Ficoll cell pellet material demonstrated an increase in 
their integrity throughout 30 days in culture, before termination of the experiment.
Figure 6: Isolated rat pancreatic islets with endogenous TSC and PSC from cell 
pellet after Ficoll density gradient centrifugation. Cell pellets were grown on 
the TSC-PSC-pancreatic matrix-B constructs utilizing the standard TSC-based 
culture medium. A & C are rat islets approximately three days after plating. B 
& D are rat islets 14 days after plating. Note that islets in B & D are increasing 
their three-dimensional integrity. These composites consisting of decellularized 
pancreatic matrix-B, Scl-44β, Scl-40β, and Ficoll cell pellet material demonstrated 
an increase in their integrity throughout 30 days in culture, before termination of 
the experiment.
Volume 1 | Issue 1 | 8 of 12J Stem Cell Res, 2017
Figure 7: Native pancreatic islets, isolated utilizing Ficoll separation (interface 
between 20 and 23% Ficoll) were plated onto type-I collagen-coated tissue culture 
plates. A & B are rat islets 48 hours after plating. C & D are rat islets 72 – 96 hours 
after plating. Note appearance of native islets pre- (A and B) and post- (C and D) 
incubation with glucose challenge. Magnifications, as noted.
Figure 8: Histogram of radioimmunoassay of insulin secretion in response to a 
glucose challenge, measured in micrograms of insulin per nanogram of DNA, 
of native islets, matrix-A composites, and matrix-B composites three days’ post 
plating. Sample sizes are n = 8 for islets alone and n = 6 for combinatorial constructs: 
Matrix (A or B) + SC (stem cells) + NI (native islets). Note, combinatorial 
constructs produced a greater insulin response per nanogram DNA than native 
islets by themselves. This occurred at all glucose concentrations examined: 5 mM 
glucose for 24 hours [Matrix A: 1.4x, Matrix B: 22x], 5 mM glucose for 1 hour 
[Matrix A: 31.6x, Matrix B: 25.3x], and 25 mM glucose for 1 hour [Matrix A: 
78.7x, Matrix B: 257.7x].
In addition, as shown in Figures 5 and 6, there was an increase in 
the integrity of the native pancreatic islets after incubation on a 
substratum of decellularized native pancreatic matrix embedded 
with clonal populations of primitive pluripotent and totipotent 
stem cells.
Cryosectioning of pancreases from naïve animals have confirmed 
the existence of pluripotent (SSEA+) and totipotent (CEA-
CAM-1+) stem cells located within the pancreatic islets of healthy 
unoperated animals (Figures 9 and 10).
Figure 9: Stage specific embryonic antigen (SSEA) and carcinoembryonic 
antigen-cell adhesion molecule-1 (CEA-CAM-1) staining of cryosectioned 
pancreas from adult porcine male (PM0010, porcine, male, 10th animal 
examined), visualized by bright field microscopy. A. SSEA positive 
stained cells overlying both islets and acinar cells. B. CEA-CAM-1 
positively stained cells overlying pancreatic islets and acinar cells. C. IA4 
positive staining for smooth muscle alpha-actin in small blood vessels 
within pancreas, utilized as the positive procedural control. D. No primary 
antibody, utilized as the negative procedural control.
Figure 10: Carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) 
and stage specific embryonic antigen (SSEA) staining of cryosectioned pancreas 
from adult male rat, visualized by bright field microscopy. A. Predominantly 
pancreatic islet overlain with (red positive) CEA-CAM-1+ cells, 200x mag. B. 
Pancreatic acinar cells overlain with (red positive) CEA-CAM-1+ cells, 200x mag. 
C. Predominantly pancreatic islet overlain with (red positive) SSEA+ cells, 200x 
mag. D. Pancreatic acinar cells overlain with (red positive) SSEA+ cells, 200x mag.
Discussion
Insulin-dependent type-I diabetes mellitus currently afflicts 16 
million Americans; whose health care expenses exceed $92 
billion per year. The mortality and morbidity due to diabetes, 
along with the associated costs of treatment, are a testament to 
the failure of traditional therapy using exogenous insulin. A 
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promising experimental cure for type-I diabetes mellitus involves 
the transplantation of insulin-producing pancreatic islet cells. 
However, potential obstacles exist that may delay using islet 
transplantation as a cure for diabetes. One obstacle is the amount 
of tissue necessary for a successful islet transplant [23]. At the 
present time, two cadaveric pancreases are necessary to supply 
the number of pancreatic islets for a successful transplant. Despite 
these limitations, the clinical benefits of islet transplantations have 
led to setting up a number of islet transplantation centers around 
the world [43]. 
The stem cell community has stepped up to meet the paucity of 
islet tissue for transplant by developing both in vitro and in vivo 
technologies for the generation of insulin-secreting beta cells from 
pluripotent stem cells. Predominantly though, this has occurred 
using pluripotent embryonic stem cells as the starting material. 
They have shown that by using recombinant inductive agents, 
small molecules, and/or miRNAs, recapitulation of development 
from an embryonic stem cell to an insulin secreting beta cell 
is theoretically possible [17]. Indeed, following the ongoing 
studies from Melton’s group [32], recent reports from Melton 
and colleagues [44-51] suggest that pancreatic beta cells can be 
generated from embryonic stem cells using a defined cocktail of 
inductive agents. Recently, VitaCyte was given FDA approval 
to begin clinical trials with embryonic stem cell-induced beta 
cells immuno-protected by alginate as an implantation treatment 
regimen for insulin-dependent diabetes. 
While using induced pluripotent embryonic stem cells as a source 
of implantable insulin-secreting beta cells for transplant is one 
approach, we have attempted an alternative approach to generating 
more islet tissue for transplant. We started with endogenous 
pluripotent stem cells derived from an adult individual, rather than 
pluripotent embryonic stem cells, and used these adult-derived 
pluripotent stem cells to generate pancreatic islets consisting of 
multiple cell types rather than just pancreatic beta cells. Initially, 
clonal populations of endogenous adult-derived stem cells 
were derived by repetitive single cell clonogenic analysis. The 
clonal populations of endogenous adult-derived stem cells were 
characterized by their differentiative potential using both in vitro 
and in vivo methods. The in vitro method entailed induction 
with either a general induction agent, such as dexamethasone at 
varying molar concentrations, or with specific inducing agents, 
such as neural growth factor, bone morphogenetic protein-2, 
vascular endothelial cell growth factor, hepatocyte growth factor, 
etc., to generate cell types from all three germ layer lineages. The 
phenotypic expression of various cell types was visualized using 
both specific antibodies and histochemical staining procedures 
[33,37,42]. Utilizing this combinatorial analysis, it was shown that 
clone Scl-40β would form 64 unique and identifiable cell types 
across all three germ layer lineages but would not form gametes, 
and thus was designated as a transitional-totipotent/pluripotent 
stem cell [36,37], whereas clone Scl-44β would form 66 unique 
and identifiable cell types, including spermatogonia and thus was 
designated as a totipotent stem cell [35]. 
Previous reports demonstrating in vivo pluripotency occurred after 
the implantation of embryonic stem cells into nude mice with the 
demonstration of teratoma formation [52]. The teratomas consisted 
of a jumbled mixture of cell types from all three germ layer 
lineages. This has been set as the gold standard that every stem cell 
must achieve to be designated as “pluripotent” [17]. We attempted 
a variation of this method by embedding the endogenous stem cell 
clones into collagen sponges and transplanting them under the skin 
in an immunologically competent outbred animal model. While 
there was no immunological rejection response from implanting 
cells from outbred animals into outbred animals, the results were 
less than desired. There was no teratoma formation and actually 
no discernible change in morphology of the stem cells. After being 
removed from the animals, released from the collagen sponges and 
placed into culture, the stem cells responded to induction factors 
by forming their respective cell types in a similar fashion as naïve 
stem cells [37]. Clearly, these naïve endogenous adult-derived 
stem cells were decidedly different from embryonic stem cells, 
with their inherent pre-programming.
We next attempted to demonstrate pluripotency by implanting 
genomically-labeled clones of stem cells into animal models of 
tissue damage. We chose three outbred animal model systems, 
cardiovascular disease [36,37] for mesodermal lineage cells; 
Parkinson disease [53] for ectodermal lineage cells; and Type-I 
diabetes [40] (current and future studies) for endodermal lineage 
cells. For the cardiovascular disease model the heart tissue was 
damaged by either freezing the apex of the heart with liquid 
nitrogen or performing transient ligation of the left anterior 
descending coronary artery. The frozen hearts were injected 
directly into the apex with genomically-labeled stem cells while 
the transient ligation model was perfused systemically with similar 
stem cells via injection into the tail vein. Both models received 
the genomically-labeled transitional-totipotent/pluripotent stem 
cell clone Scl-40β. The results from both studies noted that 
the genomically-labeled stem cells replaced damaged cardiac 
myocytes, the connective tissue skeleton of the heart and the 
vasculature, the cell types normally present in the heart and 
the particular cell types damaged in the two model systems. In 
addition, no other genomically-labeled non-cardiac cell types were 
present within the stem cell injected hearts [36,37]. 
For the Parkinson disease model the genomically-labeled 
transitional-totipotent/pluripotent stem cell clone Scl-40β or 
vehicle control were stereotactically implanted ipsilaterally 
into the midbrains of outbred rats two weeks after the unilateral 
stereotactic injection of the neurotoxin 6-hydroxydopamine into 
their respective substantia nigra. The vehicle control injected 
animals showed the formation of only a glial scar at the needle 
injection site. The experimental animals were shown to have 
tyrosine-containing genomically-labeled neurons at the injection 
site. Additional and unexpected results showed genomically-
labeled pyramidal neurons, interneurons, and astrocyte and 
oligodendrocyte glial cells in all areas that had sustained previous 
damage due to the stereotactic injections of the neurotoxin and 
the stem cells. In addition, genomically-labeled endothelial cells 
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were also present lining blood-filled capillaries in the areas where 
tissue damage occurred. These results suggested that the injected 
stem cells replaced the particular cell types (ectodermal-origin 
and mesodermal-origin cell types) that were damaged in the 
procedures used to create and treat the Parkinson disease model. 
No other genomically-labeled cell types were present within the 
tissue sections [53].
For the Type-I Diabetes model streptozotocin-induced diabetic 
animals were to be treated with the genomically-labeled stem cell 
clone Scl-40β to restore euglycemia in these animals. However, we 
first needed to prove that the Scl-40β clone would form functionally 
active pancreatic islet structures. The first step was accomplished 
using mixtures of conditioned media and known inductive agents 
to step-wise induce pluripotent stem cells to become endodermal 
stem cells, induced by using conditioned medium from endodermal 
stem cells; then to become pancreatic progenitor cells, induced 
by using conditioned medium from pancreatic progenitor cells; 
and finally to become pancreatic islet-like structures, induced by 
using the islet inductive cocktail of Bonner-Weir et al. [30]. The 
formed islet-like structures contained glucagon-secreting alpha 
cells, insulin-secreting beta cells and somatostatin-secreting delta 
cells [40]. Upon sequential challenge with glucose following the 
protocol by Lumelsky et al. [31], the induced islet-like structures 
secreted insulin at 25% to 50% insulin secretion of native islets 
challenged sequentially with glucose. 
Our next step was to create functionally active implantable 
scaffoldings for pancreatic islet induction. As noted herein, we 
utilized decellularized xenogeneic porcine extracellular matrices 
(Figure 3) in conjunction with the outbred Sprague-Dawley clones, 
transitional-totipotent/pluripotent stem cell clone Scl-40β and 
totipotent stem cell clone Scl-44β, and donor inbred Wistar-Furth 
islets and associated SSEA+ and CEA-CAM-1+ stem cells. These 
entities formed a combinatorial organoid-like structures (Figures 5 
and 6) that secreted insulin in response to a glucose challenge at far 
greater levels than control Wistar-Furth islets (Figure 7) with their 
associated stem cells by themselves (compare insulin responses, 
Figure 8). 
The current study demonstrated that insulin secreting pancreatic 
islet-like constructs could be formed from native (donor) islets, 
autologous primitive adult stem cells (derived from the recipient), 
and decellularized porcine pancreatic matrices and that these 
composite organoids are responsive to a secretagogue glucose 
challenge by secreting more insulin per nanogram DNA than 
individual native islets and their associated endogenous stem 
cells alone. Thus, these constructs have the potential for use 
in supplementing individual native islets for transplantation 
therapy, by reducing the amount of donor islet tissue required for 
transplantation. Also, we noted that the material routinely discarded 
for islet transplantation therapy, i.e., the pelleted containing the 
“trashy” material actually contained more viable islets and that 
they were invested with both CEA-CAM-1+ cells (totipotent 
stem cells) and SSEA+ cells (pluripotent stem cells) (Figure 4). 
While these culture experiments need to be proven in large animal 
studies to demonstrate restoration of euglycemia in diabetically-
induced large animal models, we would hypothesize that by using 
composites composed of decellularized FDA-approved xenogeneic 
pancreatic matrices, autologous pluripotent and totipotent stem 
cells from the recipient, allogeneic pluripotent and totipotent stem 
cells from the donor, and allogeneic pancreatic islets from the 
donor, more individuals could be transplanted per donor pancreas 
than has been previously shown. In addition, since these composite 
pancreatic islet organoid structures contained at least three of the 
cell types present in pancreatic islets, i.e., glucagon-positive alpha 
cells, insulin-positive beta cells, and somatostatin-positive delta 
cells, that a higher degree of euglycemia might be achievable 
when using these composites. 
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